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Cardiac Complications in Immune
Checkpoint Inhibition Therapy
Kazuko Tajiri* and Masaki Ieda
Department of Cardiology, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan
Immune checkpoint inhibitors (ICIs) have changed the treatment landscape of advanced
cancers. Unfortunately, these agents can induce a wide spectrum of immune-related
adverse events (irAEs) through activation of immune responses in non-target organs,
including the heart. As the clinical use of ICI therapy increases rapidly, management
of irAEs is becoming extremely important. The most commonly presented cardiac
irAE is myocarditis. Histopathologically, T-cell (with a predominance of CD8+ cells)
and macrophage infiltration in the myocardium is typically observed in ICI-associated
myocarditis. Other presentations of cardiac irAEs include congestive heart failure,
Takotsubo cardiomyopathy, pericardial disease, arrhythmias, and conduction disease.
Although cardiac irAEs are relatively rare, they can be life-threatening. Hence,
cardiologists and oncologists should be vigilant for these presentations.
Keywords: immune checkpoint inhibitors, myocarditis, cardiotoxicity, programmed cell death protein 1, cytotoxic
T-lymphocyte antigen 4, immune-related adverse events, immune checkpoint, autoimmunity
INTRODUCTION
Immune checkpoint inhibitors (ICIs), including monoclonal antibodies (mAbs) against cytotoxic
T-lymphocyte-associated antigen 4 (CTLA-4), programmed cell death protein 1 (PD-1), and
programmed cell death ligand 1 (PD-L1), are being routinely used in clinical settings and have
shown unprecedented efficacy in treating multiple cancers (1–6). Unfortunately, these agents
can induce a wide spectrum of immune-related adverse events (irAEs) (7–9) through activation
of immune responses in non-target organs, including the heart. In recent years, several cases
of cardiotoxicity have been reported in cancer patients treated with ICIs (10–17). Although its
frequency is lower than that for other irAEs, cardiotoxicity can become life-threatening, making
it an important consideration for cardiologists, oncologists, and immunologists.
In this review, we describe the mechanisms and summarize the reported clinical scenarios of
cardiotoxicities associated with ICIs. Evidence available for diagnosis, management, and prognosis
are considered.
PHYSIOLOGICAL ROLES OF IMMUNE CHECKPOINTS
T lymphocytes play a pivotal role as modulators and effectors of the immune system. Naïve T
cells are activated after recognizing a cognate peptide presented by antigen-presenting cells (APCs)
via interaction between the major histocompatibility complex (MHC) on the APCs and the T cell
receptor (TCR), but further co-stimulatory signals are required for activation. CD28 is a stimulatory
co-receptor expressed on T cells. Binding of CD80 (also known as B7-1) or CD86 (also known as
B7-2) molecules on APCs with CD28 molecules provides an essential signal for T cell activation.
However, to prevent destructive immune activation, these signals are finely regulated by immune
checkpoints (e.g., CTLA-4 and PD-1) (18).
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CTLA-4
CTLA-4 is an inhibitory co-receptor expressed on activated
T cells. CTLA-4 inhibits T cell functions by competing with
CD28 for binding with B7 ligands, CD80, and CD86. CTLA-4 is
homologous to CD28 but has much higher binding affinity and
avidity for B7 ligands. In resting naïve T cells, unlike CD28, which
is constitutively expressed on the cell surface, CTLA-4 is localized
primarily in intracellular vesicles (19). CTLA-4 is upregulated on
the cell surface in response to TCR activation and the signal is
enhanced by co-stimulation through CD28 and/or interleukin-2
(20). Of note, the stronger the TCR signal, the greater the CTLA-
4 translocation to the cell surface, thereby preventing harmful T
cell activation (19–21).
PD-1:PD-L1/2 Pathway
PD-1 is another inhibitory receptor and plays a pivotal role in
regulating the effector phase of T cell responses through binding
with its ligands PD-L1 and programmed death ligand 2 (PD-
L2) (21). PD-L1 is expressed constitutively on hematopoietic
cells and a wide range of non-hematopoietic cells, including
hepatocytes, astrocytes, epithelial cells, muscle cells including
cardiomyocytes, vascular endothelial cells, and pancreatic cells
(22, 23). PD-L1 is also expressed on numerous tumors, and its
expression is reported to be associated with poor prognosis in
several cancers (24–26). In contrast to PD-L1, PD-L2 is expressed
primarily on APCs and certain B cell lymphomas (20, 21).
Similar to CTLA-4 signaling, PD-1 signaling abrogates T cell
proliferation and cytokine production and reduces T cell survival
(23). PD-1 exhibits minimal expression on resting immune cells.
However, upon activation, PD-1 expression is induced on the
surface of T cells, B cells, natural killer cells, natural killer T cells,
dendritic cells, and macrophages (23).
IMPLICATIONS OF BLOCKING THE
CTLA-4 AND PD-1 PATHWAYS IN CANCER
To date, six ICIs have been approved by the United States
Food and Drug Administration: ipilimumab (anti-CTLA-4
mAb); nivolumab and pembrolizumab (anti-PD-1 mAbs); and
atezolizumab, avelumab, and durvalumab (anti-PD-L1 mAbs)
(Table 1). Antibody therapies against the CTLA-4 and PD-
1/PD-L1 axes have revolutionized the treatment of cancer
(Figure 1).
Cancer is characterized by genetic mutations that can
lead to the expression of various tumor-associated antigens.
APCs present these antigens via MHC molecules expressed
on their surface, which interact with TCRs. Thus, T cells can
recognize tumor-associated antigens as “non-self ” and attack
tumor cells expressing these antigens (27). However, CTLA-4
inhibits T cell activation and clonal expansion. In the tumor
immunotherapy setting, CTLA-4-targeting mAbs support the
Abbreviations: α-MHC, myosin heavy chain α isoform; APC, antigen-presenting
cells; CTLA-4, cytotoxic T-lymphocyte-associated antigen 4; ICI, immune
checkpoint inhibitor; irAE, immune-related adverse event; mAb, monoclonal
antibody; PD-1, programmed cell death protein 1; PD-L1, programmed cell death
ligand 1; TCR, T cell receptor.
activation and proliferation of effector T cells, resulting in broad
activation of immune responses against tumor cells (28). In
contrast, CTLA-4 blockade inhibits regulatory T cell-mediated
immunosuppression (28). These are thought to be the main
mechanisms of action of CTLA-4 blockade.
PD-1 is expressed on tumor-infiltrating lymphocytes in many
cancers. Chronic or high exposure to tumor antigens can induce
persistent PD-1 expression, which leads to a state of exhaustion
or anergy (lack of response). PD-1 blockade may reverse anergy
of tumor-specific T cells. PD-1 is upregulated on the cell
surface of many different tumor types. Tumor PD-L1 expression
indicates an active tumor immune microenvironment and is
strongly associated with efficacious responses to PD-1- and PD-
L1-targeting mAbs (29). It is commonly accepted that PD-L1
expression on tumors and immune cells can inhibit the T-cell
antitumor response and facilitate cancer development. However,
the role of PD-L2 in antitumor immunity remains controversial
(30, 31).
irAEs
Due to the central role played by immune checkpoints in the
maintenance of self-tolerance, immune checkpoint blockade
can induce a spectrum of adverse events, called irAEs (32).
Remarkably, irAEs can affect almost any organ system (Figure 2)
and have been reported at a substantially high frequency. irAEs
occur in up to 90% of patients (10–15% grade 3/4) treated with
ipilimumab (1) and 79% of patients (13% grade 3/4) treated
with pembrolizumab (3). In a meta-analysis, the incidence was
reported to be 75% in patients treated with CTLA-4-targeting
mAbs and 30% for PD-1- and/or PD-L1-blockingmAbs (33). The
frequency of grade 3/4 irAEs was substantially higher in patients
treated with a combination of ipilimumab and nivolumab
(54%) than in those receiving ipilimumab monotherapy (20%)
(34).
irAEs are generally managed with corticosteroids, and less
commonly, with other immunomodulatory agents (35). There
are no prospective studies that have investigated management
strategies for irAEs. According to the various organs involved,
grade 1–2 events mainly affect the gut and skin, whereas
grade 3–4 events are mainly restricted to the digestive tract.
Cardiac, neurologic, renal, ocular, and hematologic irAEs are
uncommon (35).
CARDIOTOXICITY ASSOCIATED WITH
IMMUNE CHECKPOINT INHIBITION
Insights From Animal Studies
During the establishment of central tolerance in the thymus,
most autoreactive T cells are deleted; however, some autoreactive
T cells are released into the periphery (36, 37). In healthy
individuals, peripheral tolerance mechanisms regulate the
numbers of these cells. CTLA-4 competes with CD28 to
downregulate T cell activation, resulting in immunotolerance and
prevention of pathologic immune responses to cardiac antigens
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TABLE 1 | FDA-approved ICIs for cancer therapy.
Target Drug Indication
CTLA-4 Ipilimumab Melanoma
PD-1 Nivolumab Melanoma, NSCLC, SCLC, RCC, HCC, Hodgkin lymphoma, head and neck cancer, urothelial
carcinoma, microsatellite instability-high, or mismatch repair-deficient metastatic colorectal cancer
PD-1 Pembrolizumab Melanoma, NSCLC, head and neck squamous cell carcinoma, Hodgkin lymphoma, urothelial
carcinoma, microsatellite instability-high cancer, gastric cancer, cervical cancer, primary mediastinal large
B-cell lymphoma
PD-L1 Atezolizumab NSCLC, urothelial carcinoma
PD-L1 Durvalumab NSCLC, urothelial carcinoma
PD-L1 Avelumab Urothelial carcinoma, Merkel cell carcinoma
CTLA-4 and PD-1 in combination Ipilimumab and
nivolumab
Melanoma, RCC, microsatellite instability-high, or mismatch repair-deficient metastatic colorectal cancer
CTLA-4, cytotoxic T lymphocyte-associated antigen 4; FDA, Food and Drug Administration; HCC, hepatocellular carcinoma; ICI, immune checkpoint inhibitor; NSCLC, non-small cell
lung cancer; PD-1, programmed cell death protein 1; PD-L1, programmed cell death ligand 1; RCC, renal cell carcinoma; SCLC, small cell lung cancer.
FIGURE 1 | Distinct roles of CTLA-4 and PD-1/PD-L1 in the regulation of antitumor immune responses. (A) Interactions between CTLA-4/B7 and PD-1/PD-L1 inhibit
T cell-mediated tumor cell killing. (B) Blockade of CTLA-4, PD-1, and PD-L1 results in T cell activation and proliferation, which reactivates T cell-mediated tumor cell
killing.
(38). Interactions between PD-1 and its ligands also maintain
cardiac-reactive T cells in an anergic state (38) (Figure 3).
Mice deficient in CTLA-4 develop severe myocarditis with
massive T cell infiltration (39). The cardiac presentation of
PD-1-deficient mice is dependent on their background; mice
on the BALB/c background develop autoimmune dilated
cardiomyopathy (40), but PD-1-deficient autoimmune-
prone MRL mice show lymphocytic myocarditis with massive
infiltration of CD4+ and CD8+ T cells (41). PD-L1 is significantly
upregulated on the surface of cardiac endothelial cells during
myocarditis. PD-L1 deficiency in MRL mice induces similar
severe myocarditis (42).
Cardiac irAEs of ICIs in Patients With
Cancer
Incidence
There are contrasting reports on the rates of cardiac irAEs
associated with ICI therapies. For example, no incidence of
myocarditis was identified after a pooled analysis of 448
patients treated with nivolumab and ipilimumab combination
therapy (43). In contrast, a pharmacovigilance study identified
myocarditis in 18 of 20,594 patients (0.09%) treated with
nivolumab alone or in combination with ipilimumab (13), and
a cohort study of 964 patients from a multicenter registry
reported a prevalence of 1.14%, which increased to as high as
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FIGURE 2 | The clinical spectrum of irAEs associated with immune checkpoint
inhibitors. irAEs, immune-related adverse events.
2.4% for combination therapy with anti-PD-1/anti-CTLA-4 (44).
According to the latter report, ICI-associated myocarditis can no
longer be considered a “rare” adverse effect. So far, ICI-associated
myocarditis appears to be a class effect, and the incidence seems
to be higher when patients are treated with a combination of ICIs
(13, 44).
Clinical Presentation and Management
The most common cardiac irAE is myocarditis (45).
Histopathologically, T cell (with a predominance of CD8+ cells)
and macrophage infiltration in the myocardium are typically
observed in ICI-related myocarditis (10, 12–15, 46). This
myocarditis sometimes involves the cardiac conduction system,
leading to conduction block. Other presentations of cardiac irAEs
include congestive heart failure, Takotsubo cardiomyopathy,
pericardial disease, arrhythmias, and conduction disease (47).
The time to onset of myocarditis is variable. An analysis of
VigiBase, theWorld Health Organization’s database of individual
case safety reports that includes 101 cases of severe myocarditis,
revealed that myocarditis was diagnosed at a median of 27 days
(range, 5–155 days) after the initiation of ICI therapy, with
76% of the cases occurring in the first 6 weeks of treatment
(48). A medical record review of 30 ICI-related cardiotoxicity
patients from two cardio-oncology units revealed that themedian
onset of cardiotoxicity was 65 days (range, 2–454 days) and it
occurred after a median of three (range, 1–33) infusions (49). In a
multicenter cohort including 35myocarditis patients, the median
time to onset was 34 days and 81% of the patients developed
cardiac irAE within 3 months (44). Notably, fatal myocarditis
can develop after only a single treatment with an ICI (11, 13).
Unfortunately, there is insufficient information regarding the
time of onset of cardiac irAEs relating to specific treatment
regimes. In general, most irAEs were reported to occur within
3–6 months of the initiation of anti-CTLA-4- or anti-PD-1-
targeting therapy (47, 50). While the risk of severe irAEs appears
to be dose-dependent with anti-CTLA-4 antibodies, toxicities
with anti-PD-1/anti-PD-L1 antibodies are reported to be dose-
independent (47, 50).
Cardiac signs and symptoms of ICI-related cardiotoxicity
vary from asymptomatic to sudden death (10–17, 51) and lack
specificity. Sometimes cardiac irAE is accompanied by other
organ irAEs, especially those in skeletal muscles (11, 13).
Currently, patients who are likely to develop cardiac irAEs
cannot be identified before ICI therapy. Therefore, early
detection of ICI-related myocarditis is thought to be important
for improved management. Mahmood et al. (44) showed that
measuring troponin levels at baseline and at each cycle of ICI
treatment may be useful for surveillance because this parameter
was abnormal in 94% of ICI-myocarditis patients at clinical
presentation. In contrast, Sarocchi et al. (52) measured troponin
levels at each nivolumab administration in 59 patients and found
an elevation in only six patients, none of whom developed overt
cardiac irAEs. These researchers mentioned possible reasons
for a “false positive” elevation of troponin, including it being
a consequence of myocardial oxygen demand-supply mismatch
due to aggravation of the clinical status or the presence of
subclinical ICI-induced myocarditis. An elevation of troponin
indicates the presence of, but not the underlying reason for,
myocardial injury. Therefore, myocarditis or other myocardial
damage should be considered in cases presenting with elevated
troponin, and these patients should be referred immediately
to cardiologists/onco-cardiologists for further evaluation (44).
Mahmood et al. (44) also reported abnormal electrocardiograms
in 89% of ICI-related myocarditis patients. In contrast, NT-
ProBNP was abnormal in 66%, and the left ventricular ejection
fraction (LVEF) was abnormal in only 49% of these patients.
Thus, NT-proBNP or LVEF may be less useful for early diagnosis
of cardiac irAEs than troponin or ECG. Information on the utility
of hsCRP as an early biomarker of cardiac irAEs is lacking.
Pharmacovigilance data show that the mortality of ICI-
associated myocarditis exceeded 60% in patients receiving
ipilimumab-nivolumab combination therapy (13). Mahmood
et al. (44) reported that nearly half of all myocarditis cases
developed a major adverse cardiac event (a combination of
cardiovascular death, cardiac arrest, cardiogenic shock, and
hemodynamically significant complete heart block). Escudier
et al. (49) reported after a medical record review of 30 ICI-related
cardiotoxicity patients that eight (27%) died of cardiovascular
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FIGURE 3 | The role of immune checkpoints in establishing peripheral tolerance to the heart. During the establishment of central tolerance in the thymus, most
autoreactive T cells are deleted; however, some autoreactive T cells are released into the periphery. In health, peripheral tolerance mechanisms keep these cells in
check. CTLA-4 competes with CD28 to downregulate T-cell activation, resulting in immunotolerance and prevention of pathologic immune responses to
cardiac-antigens. PD-1-PD-1 ligand interactions also maintain the cardiac-reactive T cells in an anergic state. Antibodies against CTLA-4, PD-1, or PD-L1 may
activate cardiac antigen-reactive T cells that escape central tolerance. These T cells can clonally expand and attack the heart.
complications. They also reported that cardiovascular mortality
was significantly associated with conduction abnormalities and
ipilimumab-nivolumab combination therapy (49).
Currently, there are no guidelines for the treatment of
cardiac irAEs. Steroids have been used to treat cardiac
irAEs in most cases (11, 13–16, 44, 45). For steroid non-
responders, other immunosuppressive agents, high-dose
intravenous immunoglobulin therapy, plasmapheresis, and
immunoadsorption therapy have been used (45, 53).
CONCLUSIONS
ICI therapies have changed the treatment landscape of advanced
cancer. As the clinical use of ICI therapy rapidly increases,
management of irAEs is extremely important. Cardiac irAEs
are relatively rare but can be life-threatening. Large scale,
prospective, and longitudinal cohort studies are needed to
clarify predisposing risk factors and long-term consequences
of ICI-induced cardiac irAEs. In addition to clinical studies,
basic studies are crucially needed to provide insights into
underlying mechanisms and to find biomarkers to identify high
risk patients and minimize the risk of ICI-associated cardiac
irAEs.
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